5 recruiting, 2 terminated. 7 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 5, Terminated 2 |
| Phase 1 | 4 | Recruiting 3, Terminated 1 |
Follow repotrectinib: new trials by email Literature Review of repotrectinib trials Research Report on repotrectinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis Repotrectinib - NSCLC, Brain Metastases | Phase 2 | Recruiting | MedSIR | 20 | 2025-06-27 | 2026-09-09 |
| Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC Repotrectinib - NSCLC Stage IV, NSCLC, Stage III | Phase 2 | Recruiting | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | 30 | 2024-10-01 | 2026-07-07 |
| Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) Fulvestrant, Repotrectinib - Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2024-08-08 | 2026-01-05 |
| A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors TPX-0005, Trametinib - KRAS Mutation-Related Tumors, Metastatic Solid Tumor | Phase 1 / Phase 2 | Terminated | Turning Point Therapeutics, Inc. | 9 | 2021-09-23 | 2024-04-02 |
| A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer Repotrectinib, Irinotecan and temozolomide - Advanced Cancer, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 77 | 2021-08-09 | 2026-06-04 |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Oral repotrectinib (TPX-0005) - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Turning Point Therapeutics, Inc. | 75 | 2020-03-12 | 2026-09-25 |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Oral repotrectinib (TPX-0005) - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Turning Point Therapeutics, Inc. | 500 | 2017-03-07 | 2026-05-27 |
Carcinoma, Non-Small-Cell Lung (3) · Neoplasm Metastasis (3) · Sarcoma (2) · Adenocarcinoma (1) · Brain Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Lobular (1) · Carcinoma, Neuroendocrine (1) · Colonic Diseases (1) · Colonic Neoplasms (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
Turning Point Therapeutics, Inc. (3) · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer (1) · M.D. Anderson Cancer Center (1) · MedSIR (1) · Memorial Sloan Kettering Cancer Center (1)
United States (5) · France (3) · Spain (3) · Australia (2) · Canada (2) · Denmark (2) · Germany (2) · Italy (2) · Singapore (2) · South Korea (2) · Taiwan (2) · United Kingdom (2) · Austria (1) · Belgium (1) · China (1)
Emily Slotkin, MD (1) · Jason Mouabbi, MD (1)
PMID 30093503, PMID 32269053, PMID 34814185, PMID 38197815, PMID 40341199, PMID 41639379
2023 (3)